Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV

Active
75N95026R0007Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This solicitation, numbered 75N95026R0007, seeks a commercial services provider to conduct a pharmacoepidemiological study evaluating the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on HIV-related outcomes and alcohol and substance use disorders in adults living with HIV, using electronic health record data from the Department of Veterans Affairs. The research will employ propensity-score matching and multivariable linear regression to assess changes in health outcomes before and after GLP-1RA exposure, with findings intended to inform future clinical trials. The contract is structured as a firm-fixed-price purchase order with a one-year base period from August 7, 2026, through August 6, 2027, and includes three optional one-year extensions through August 6, 2030. The scope of work requires the contractor to manage and analyze de-identified VA data under strict security protocols, with no personally identifiable information permitted to leave VA systems, and to support the development of conference abstracts and peer-reviewed publications led by NIDA and its collaborators. All deliverables must consist of aggregate-level results only, ensuring compliance with federal data privacy requirements. The solicitation is full and open with no set-aside, classified under NAICS code 541690 with a small business size standard of $19 million in annual receipts. Proposals must include a technical submission demonstrating capability to perform the research, a detailed price proposal with labor categories, estimated hours, fully loaded rates, and other direct cost breakdowns, and must be submitted electronically by 9:00 a.m. EST on July 30, 2026, to Robin.Knightly@nih.gov. All offerors must maintain active registration in SAM, provide their UEI and TIN, and certify compliance with multiple FAR provisions governing ethics, whistleblower protections, equal opportunity, labor standards, cybersecurity, trafficking in persons, and prohibitions on internal confidentiality agreements. Technical capability and past performance are significantly more important than price in the evaluation, with award going to the most advantageous offer based on overall value. The contract incorporates numerous FAR clauses addressing subcontracting, payment by electronic funds transfer, service contract labor standards, and data security, and requires strict adherence to VA data handling protocols and federal compliance standards. No physical delivery or packaging requirements are specified, and the place of performance is Bethesda, Maryland.

General Info

Contract for pharmacoepidemiological study on GLP-1RAs and HIV outcomes using VA data, firm-fixed-price, one year with extensions.

Agency

Department Of Health And Human Services → National Institutes Of Health NidaView Agency

NAICS

541690 - Other Scientific and Technical Consulting ServicesView NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(2)

SOW for GLP-1RAs Study on HIV and Substance Use Disorders

PDFsow

RFP 75N95026R0007 Role of GLP-1 Receptor Agonists for HIV Outcomes

PDFrfp

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseCombined Synopsis
Posted

Combined Synopsis

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Nida
Contacts1 person available
OfficeBethesda, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Nida
View Agency Profile
Office AddressBethesda, MD, 20892, USA
Contacts

Full Description

Show more

COMBINED SYNOPSIS / SOLICITATION (COMPETITIVE)


Title:  Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors   for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV 


(i) This is a combined synopsis/solicitation for commercial items. This announcement constitutes the only solicitation; a written solicitation will not be issued.


(ii) The solicitation number is 75N95026R0007. This solicitation is issued as a request for proposal (RFP).


(iii) This solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2026-01.


(iv) This requirement is full and open with no set-aside restrictions.  The associated NAICS Code is 541690 Other Scientific and Technical Consulting Services and the small business size standard is $19.0M.


(v) The Government anticipates award of a firm fixed-price purchase order for the services acquired under this acquisition, and the anticipated period of performance is August 7, 2026 through August 6, 2027 with three (3) twelve-month option periods.


(vi) Description of Requirement:


The objective of the proposed project is to examine GLP-1RAs and their potential health benefits for PLWH, in addition to alcohol and substance use disorders outcomes. Using electronic health record data from the Department of Veterans Affairs (VA), the largest integrated healthcare system in the US, we will investigate the association between GLP-1RAs (prescribed for any indication) and HIV- and ASUD-related outcomes in adults. Individuals exposed to GLP-1RAs will be propensity-score matched to up to five unexposed individuals. Multivariable linear regression models will estimate changes in HIV- and ASUD-related outcomes before and after exposure.


See attached Statement of Work for Specific Requirements


(vii) Delivery:


See attached Statement of Work for Specific Delivery or Deliverables.


(viii) The provision at RFO 52.212-1, Instructions to Offerors—Commercial Products and Commercial Services, applies to this acquisition.


(ix) The provision at RFO 52.212-2, Evaluation—Commercial Products and Commercial Services, applies to this acquisition.


(a) Evaluation Factors.  The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be the most advantageous to the Government , price and other factors considered.  The following factors will be used to evaluate offers:


  • Technical capability
  • Price
  • Past performance

Evaluation factors other than price when combined are significantly more important than price.


(b) Options.  The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement.  The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced.  The evaluation of options does not obligate the Government to exercise the option(s).


(c) Notice of award.  A written notice of award or acceptance of an offer furnished to the successful Offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party.  Before the offer’s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award.


(x) The clause at RFO 52.212-4, Contract Terms and Conditions – Commercial Products and Commercial Services, applies to this acquisition.


(xi) System updates may lag policy updates.  The System for Award Management (SAM) may continue to require entities to complete representations based on provisions that are not included in this solicitation.  Contracting officers will rely on representations from offers based on provisions in the solicitation.  Entities are not required to, nor are they able to update their entity registration to remove these representations in SAM.


(xii) No additional contract requirement(s) or terms and conditions have been determined by the contracting officer to be necessary for this acquisition and consistent with customer commercial practices.


(xiii) The Defense Priorities and Allocations System (DPAS) is not applicable.


(xiv) Submission Requirements:


Responses to this solicitation must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount.


(xv) The provision at RFO 52.251-1 Solicitation Provisions Incorporated by Reference (Feb 1998) applies to this solicitation.


This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this/these address(es): www.acquisition.gov


The following provisions apply to this acquisition and are incorporated by reference:


  • 52.203-11 Certification and Disclosure Regarding Payments to Influence Certain Federal Transactions
  • 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements or Statements-Representation
  • 52.204-7 System for Award Management – Registration
  • 52.204-90 Offeror Identification
  • 52.222-52 Exemption from Application of the Service Contract Labor Standards for Certain Services-Certification
  • 52.217-8 Option to Extend Services
  • 52.217-9 Option to Extend the Term of the Contract
  • 52.223-4 Recovered Material Certification
  • 52.240-90 Security Prohibition and Exclusions Representations and Certifications

(xvi)  The clause at RFO 52.252-2, Clause Incorporated by Reference (Feb 1998) applies to this solicitation.


This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es): www.acquisition.gov


The following clauses apply to this acquisition and are incorporated by reference:


  • 52.203-6 with Alt 1 Restrictions on Subcontractor Sales to the Government
  • 52.203-17 Contractor Employee Whistleblower Rights
  • 52.203-19 Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements
  • 52.204-13 System for Award Management- Maintenance
  • 52.204-91 Contractor Identification
  • 52.209-6 Protecting the Government’s Interest When Subcontracting with Contractors, Debarred, Suspended, or Proposed for Debarment
  • 52.209-10 Prohibition on Contracting with Inverted Domestic Corporations
  • 52.219-4 Notice of Price Evaluation Preference for HUBZone Small Business Concerns
  • 52.219-8 Utilization of Small Business Concerns
  • 52.222-3 Convict Labor
  • 52.222-35 Equal Opportunity for Veterans
  • 52.222-36 Equal Opportunity for Workers with Disabilities
  • 52.222-37 Employment Reports on Veterans
  • 52.222-40 Notification of Employee Rights Under the National Labor Relations Act
  • 52.222-41 Service Contract Labor Standards
  • 52.222-42 Statement of Equivalent Rates for Federal Hires
  • 52.222-43 Fair Labor Standards Act and Service Contract Labor Standards-Price Adjustment (Multiple Year and Option Contracts)
  • 52.222-44 Fair Labor Standards Act and Service Contract Labor Standards-Price Adjustment
  • 52.222-50 Combating Trafficking in Persons
  • 52.222-54 Employment Eligibility Verification
  • 52.222-62 Paid Sick Leave Under Executive Order 13706
  • 52.222-90 Addressing DEI Discrimination by Federal Contractors
  • 52.226-8 Encouraging Contractor Policies to Ban Text Messaging While Driving
  • 52.232-33 Payment by Electronic Funds Transfer-System for Award Management
  • 52.232-40 Providing Accelerated Payment to Small Business Subcontractors
  • 52.233-3 Protest After Award
  • 52.233-4 Applicable Law for Breach of Contract Claim
  • 52.240-91 Security Prohibitions and Exclusions
  • 52.240-93 Basic Safeguarding of Covered Contractor Information Systems
  • 52.244-6 Subcontracts for Commercial Products and Commercial Services

Responses must include the Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and business size certification. All offerors must be actively registered in the System for Award Management (SAM) at www.sam.gov.


(xv) All responses must be received by 9:00 a.m. EST on July 30, 2026 and must reference solicitation number 75N95026R0007. Responses must be submitted electronically to Robin.Knightly@nih.gov.


(xvi) Point of Contact:


Robin Knightly, Contracting Officer, Robin.Knightly@nih.gov


Attachment(s)


1. Statement of Work (SOW)
 

Similar Contracts

Same NAICS industry code

NAICS: 541690
New
DIBBS
Hazardous Materials Compliance and LabelingThis contract requires full compliance with OSHA’s Hazard Communication Standard and DFARS 252.223-7001 for the proper labeling of hazardous materials and the accurate management of Safety Data Sheets. It mandates the implementation and maintenance of a comprehensive hazard communication program that ensures all employees and stakeholders are informed of chemical hazards through standardized labels, SDS availability, and training protocols. The scope includes end-to-end regulatory adherence for hazardous substances used or handled under the contract, with specific attention to documentation accuracy, timely updates, and consistent application across all work sites. The contract is structured as a subcontract under a Total Small Business Set-Aside, exclusively available to small businesses certified by the SBA, and is classified under NAICS code 541690 for other scientific and technical consulting services. It was posted by the Department of Defense’s Strategic Acquisition Program Directorate and requires responses to be submitted by July 28, 2026. Performance is expected to support defense-related operations, though the precise location of performance is not specified. The effort centers on ensuring regulatory rigor in hazardous material handling, with an emphasis on safety, compliance, and accountability under federal defense contracting requirements.
STRATEGIC ACQ PROGRAM DIRECTORATE

POSTED

1 day ago

DEADLINE

in 4 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Nida

Same awarding agency

NAICS: 541990
Federal
Notice of Ordering Period Extension-Clinical Evaluation of Phenserine Tartrate Extended Controlled Release TabletThe National Institute on Aging intends to extend the ordering period of its existing IDIQ contract with the University of Exeter, UK, by one year, moving the deadline from August 1, 2026, to August 1, 2027, to ensure completion of planned clinical work under Task Orders 2 and 3. This contract supports the clinical evaluation of (-)-Phenserine tartrate Extended Controlled Release Tablet (ECRT) in two patient populations: individuals with early mild Alzheimer’s disease and those with mild to moderate traumatic brain injury. The study involves phase 1/2 clinical trials to assess pharmacokinetic and pharmacodynamic profiles, including steady-state drug concentrations, target engagement, tolerability, and biomarker outcomes through blood sampling, cognitive testing, and brain imaging. The contractor will deliver all necessary personnel, facilities, and resources to administer the drug under rigorously controlled conditions, with the government providing the drug substance, including an immediate-release formulation if needed to achieve target plasma levels. The work is non-competitive, authorized under 41 U.S.C. 3304(a)(1) and aligned with RFO Subpart 6.103-1, as the University of Exeter is the only responsible source capable of delivering the required expertise. The contract is classified under NAICS code 541990 with a $19.5 million size standard, and no follow-on procurements are anticipated. All responses to this presolicitation notice must be submitted electronically by July 30, 2026, to the designated contracting officer, and require an active SAM registration, UEI, TIN, and business size certification.
All Other Professional, Scientific, and Technical Services

POSTED

9 days ago

DEADLINE

in 6 days
View Details